• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因多态性与伊马替尼治疗慢性髓性白血病反应的相关性:一项荟萃分析。

gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.

机构信息

Blood Bank, Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia.

Department of Medical Genetic, Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia.

出版信息

J Oncol Pharm Pract. 2022 Jan;28(1):39-48. doi: 10.1177/1078155220981150. Epub 2021 Feb 10.

DOI:10.1177/1078155220981150
PMID:33565361
Abstract

BACKGROUND

Our study aimed to investigate the association between multidrug resistance (MDR1) C1236T, C3435T and G2677T/A polymorphisms and the response to imatinib (IM) in chronic myeloid leukemia (CML).

MATERIALS AND METHODS

An electronic databases in PubMed, Embase, Web of Knowledge, Scopus and Cochrane were searched using combinations of keywords relating to MDR1 polymorphisms and the response to IM in CML. Studies retrieved from database searches were screened using strict inclusion and exclusion criteria.

RESULTS

In total, 37 studies were initially identified, and 17 studies, involving 4494 CML patients, were eventually included in this meta-analysis.Results of our study revealed significant association between MDR1 G2677T/A and C3435T polymorphisms and response to IM in Caucasian population under recessive model (T or A vs G; OR = 1.43,95%CI [1;06-1.93]; T vs C;OR = 1.13; 95%IC [0.79; 1.63]), dominant (T or A vs G; OR = 0.94; 95%CI [0.74-1.21]; T vs C; OR = 1.49; 95%CI [1.02-2.17]) and heterozygous models (T or A vs G; OR = 0.83; 95%CI [0.64; 1.09]; T vs C; OR = 1.52; 95%CI [1.01-2.28]); respectively. However, never significative association was found between IM response and the MDR1 C1236T polymorphism (OR = 1.25; 95%CI [0.46; 3.33]).

CONCLUSION

The MDR1 G2677T/A and C3435T polymorphisms might be a risk factor for resistance to IM in Caucasian CML patients.

摘要

背景

本研究旨在探讨多药耐药基因(MDR1)C1236T、C3435T 和 G2677T/A 多态性与伊马替尼(IM)治疗慢性髓系白血病(CML)反应之间的关系。

材料和方法

在 PubMed、Embase、Web of Knowledge、Scopus 和 Cochrane 电子数据库中,使用与 MDR1 多态性和 CML 中 IM 反应相关的关键词组合进行了搜索。从数据库检索中筛选出符合严格纳入和排除标准的研究。

结果

共初检到 37 项研究,最终纳入了 17 项研究,共计 4494 例 CML 患者。我们的研究结果表明,在白种人群中,MDR1 G2677T/A 和 C3435T 多态性与 IM 反应之间存在显著相关性,在隐性模型下(T 或 A 与 G 相比;OR=1.43,95%CI [1;06-1.93];T 与 C 相比;OR=1.13;95%CI [0.79;1.63])、显性模型(T 或 A 与 G 相比;OR=0.94;95%CI [0.74-1.21];T 与 C 相比;OR=1.49;95%CI [1.02-2.17])和杂合模型(T 或 A 与 G 相比;OR=0.83;95%CI [0.64;1.09];T 与 C 相比;OR=1.52;95%CI [1.01-2.28])。然而,IM 反应与 MDR1 C1236T 多态性之间从未发现显著相关性(OR=1.25;95%CI [0.46;3.33])。

结论

MDR1 G2677T/A 和 C3435T 多态性可能是白种人 CML 患者对 IM 耐药的危险因素。

相似文献

1
gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.基因多态性与伊马替尼治疗慢性髓性白血病反应的相关性:一项荟萃分析。
J Oncol Pharm Pract. 2022 Jan;28(1):39-48. doi: 10.1177/1078155220981150. Epub 2021 Feb 10.
2
Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.多药耐药基因(MDR1)多态性可能与慢性髓性白血病患者对伊马替尼的反应无直接关联。
Genet Mol Res. 2015 Nov 24;14(4):14967-78. doi: 10.4238/2015.November.24.4.
3
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.MDR1 基因多态性与慢性髓性白血病伊马替尼反应的关系:一项荟萃分析。
Pharmacogenomics. 2014 Apr;15(5):667-77. doi: 10.2217/pgs.13.222.
4
Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.MDR1和CYP3A5基因多态性对新诊断慢性髓性白血病患者伊马替尼谷浓度及治疗反应的影响。
Pharmacol Res. 2017 Jun;120:138-145. doi: 10.1016/j.phrs.2017.03.011. Epub 2017 Mar 19.
5
Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?多药耐药基因1(MDR1)和细胞色素P450 3A5(CYP3A5)基因的多态性是否会影响接受伊马替尼治疗的慢性髓性白血病患者细胞遗传学复发的风险?
Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2017.1287359. Epub 2017 Apr 3.
6
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.谷浓度和ABCG2基因多态性能更好地预测慢性髓性白血病对伊马替尼的反应:一项荟萃分析。
Pharmacogenomics. 2017 Jan;18(1):35-56. doi: 10.2217/pgs-2016-0103. Epub 2016 Dec 19.
7
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.多药转运体基因 ABCB1 和 ABCG2 的基因型和单倍型与慢性髓性白血病患者甲磺酸伊马替尼临床反应的相关性。
Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.
8
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.人类有机阳离子转运体和多药耐药基因的多态性:与慢性髓性白血病患者伊马替尼水平及临床病程的相关性
Leuk Lymphoma. 2014 Nov;55(11):2525-31. doi: 10.3109/10428194.2014.893307. Epub 2014 Mar 19.
9
ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.ABCB1单倍型而非单个单核苷酸多态性可预测接受甲磺酸伊马替尼治疗的埃及慢性期慢性髓性白血病患者的最佳反应/治疗失败情况。
Med Oncol. 2014 Nov;31(11):279. doi: 10.1007/s12032-014-0279-y. Epub 2014 Oct 11.
10
Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.埃及慢性髓性白血病患者中MDR1基因多态性(G2677T)与伊马替尼反应的关联
Hematology. 2014 Apr;19(3):123-8. doi: 10.1179/1607845413Y.0000000102. Epub 2013 Nov 25.

引用本文的文献

1
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.ABCA 和 SLC 转运蛋白基因的遗传变异与慢性髓性白血病:对易感性和预后的影响。
Int J Mol Sci. 2022 Aug 29;23(17):9815. doi: 10.3390/ijms23179815.
2
Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients' CD34/CD38 Leukemia Stem Cells.新型二羧酰亚胺BK124.1克服多药耐药性,并在慢性髓性白血病临床前模型和患者的CD34/CD38白血病干细胞中显示出抗癌疗效。
Cancers (Basel). 2022 Jul 27;14(15):3641. doi: 10.3390/cancers14153641.